These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10442347)

  • 1. Chemotherapy combination shows efficacy in hormone-refractory prostate cancer.
    Oncology (Williston Park); 1999 Jul; 13(7):1014. PubMed ID: 10442347
    [No Abstract]   [Full Text] [Related]  

  • 2. Controversies in chemotherapy of prostate cancer.
    Heicappell R
    Front Radiat Ther Oncol; 2002; 36():72-80. PubMed ID: 11842757
    [No Abstract]   [Full Text] [Related]  

  • 3. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Smith DC
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
    Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
    Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy in hormone-refractory prostate cancer.
    Petrylak DP
    Curr Oncol Rep; 2001 Sep; 3(5):417. PubMed ID: 11489242
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of chemotherapy in advanced prostate cancer.
    Ernst DS
    Can J Urol; 2002 Jun; 9 Suppl 1():21-5. PubMed ID: 12121591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taxanes in hormone-refractory prostate cancer.
    Kang MH; Figg WD; Dahut W
    Cancer Pract; 1999; 7(5):270-2. PubMed ID: 10687598
    [No Abstract]   [Full Text] [Related]  

  • 9. [Chemotherapy of prostate cancer: potential role of docetaxel].
    Bracarda S
    Tumori; 2001; 87(6):A12-4. PubMed ID: 11995697
    [No Abstract]   [Full Text] [Related]  

  • 10. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
    Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
    Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
    Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel in prostate cancer.
    Small EJ
    Anticancer Drugs; 2001 Feb; 12 Suppl 1():S17-20. PubMed ID: 11340899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel (Taxotere) in hormone-refractory prostate cancer: a new addition to the physicians' toolbag.
    Vogelzang NJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):1-2. PubMed ID: 10604260
    [No Abstract]   [Full Text] [Related]  

  • 14. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
    Petrylak DP; Macarthur R; O'Connor J; Shelton G; Weitzman A; Judge T; England-Owen C; Zuech N; Pfaff C; Newhouse J; Bagiella E; Hetjan D; Sawczuk I; Benson M; Olsson C
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):28-33. PubMed ID: 10604266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy for hormone-refractory prostate cancer].
    Nishimura K; Takahara S; Nonomura N; Okuyama A
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():266-71. PubMed ID: 12599583
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
    Savarese D; Taplin ME; Halabi S; Hars V; Kreis W; Vogelzang N
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):39-44. PubMed ID: 10604268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].
    Kimura M; Sasagawa T; Tomita Y; Katagiri A; Morishita H; Saito T; Tanikawa T; Kawasaki T; Saito K; Nishiyama T; Kasahara T; Hara N; Takahashi K
    Hinyokika Kiyo; 2003 Dec; 49(12):709-14. PubMed ID: 14978952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy for prostate cancers].
    Naito K
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():205-10. PubMed ID: 12599572
    [No Abstract]   [Full Text] [Related]  

  • 20. Taxing the taxanes: overused or undersold?
    Miller M
    J Natl Cancer Inst; 1999 Dec; 91(24):2077-8. PubMed ID: 10601377
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.